H.R. 6561: Promoting Resources to Expand Vaccination, Education and New Treatments for HPV Cancers Act of 2025

This bill, known as the Promoting Resources to Expand Vaccination, Education and New Treatments for HPV Cancers Act of 2025, aims to enhance public awareness and education regarding human papillomavirus (HPV) and its links to various types of cancers. The primary components of the bill can be summarized as follows:

Findings

The bill outlines several findings regarding HPV and its impact, including:

• HPV is responsible for six different types of cancer, including cervical and anal cancers.
• Every year, around 39,300 cases of cancer are attributable to HPV.
• Significant disparities exist in the incidence of HPV-associated cancers, particularly among Black and Hispanic women.
• HPV vaccination has been shown to reduce the incidence of cervical cancer, although the rates of new cases in older women have recently plateaued.
• Cervical cancer screenings are declining, leading to more advanced-stage diagnoses.
• Vaccination is most effective when given to individuals aged 9 to 12, yet completion rates for the vaccination series are lower than for other vaccines.

HPV Cancer Prevention Public Awareness Campaign

The bill mandates the creation of a national public awareness campaign led by the Secretary of Health and Human Services, through the Centers for Disease Control and Prevention (CDC), with specific goals to:

• Increase awareness of the importance of HPV vaccination.
• Combat misinformation surrounding HPV vaccinations.
• Boost HPV vaccination rates.

This campaign will involve collaboration with various stakeholders, including healthcare providers, public health organizations, and community representatives, to ensure effective outreach. Key features of the campaign will include the development of resources tailored to high-risk communities, use of various media platforms, and employing culturally competent messaging.

Funding and Coordination

The bill authorizes $5 million in appropriations per fiscal year from 2026 through 2030 to support the campaign. Additionally, it mandates a report to Congress detailing the campaign's effectiveness no later than September 30, 2027.

Breast and Cervical Cancer Early Detection Program

In the context of breast and cervical cancer detection, the bill amends existing legislation to increase funding for early detection programs from $275 million for fiscal year 2012 to $300 million for each fiscal year from 2026 through 2030. This adjustment is intended to ensure continued support for cancer screening initiatives.

Summary of Legislative Goals

Overall, the bill seeks to:

• Promote the HPV vaccination as a critical tool for preventing several types of cancers.
• Improve public knowledge and fight misinformation regarding HPV and its vaccines.
• Increase accessibility to HPV vaccinations, particularly among underserved populations.
• Support ongoing cancer detection efforts through appropriate funding.

Relevant Companies

• PFE - Pfizer, Inc.: The company manufactures the HPV vaccine, which could see increased demand as awareness campaigns promote vaccination.
• MRK - Merck & Co., Inc.: Merck also produces an HPV vaccine, and enhanced vaccination rates could positively impact its sales and market position.